Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

Completed

Conditions studied: Hepatitis C

In brief

Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients. There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).

Key facts

Study ID

NCT01429155

Run by

Henry Ford Health System

People needed

36

Starts

2011-08-01

Expected to finish

2013-03-01

Last updated by the study team

2014-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who received a living donor liver transplant for chronic hepatitis C who are 18 year or older
• Patients who donated part of their liver to patients suffering from chronic hepatitis C. Donors must be 18 years or older

You may not qualify if…

• Patients who are not willing to sign the consent
• Inability to obtain liver specimen (recipients)
• Inability to obtain blood sample (donors)

Where it is running

• Henry Ford Hospital — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.